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Abstract
Background: Interferon-gamma release assays (IGRAs) have provided a new method for the diagnosis of Mycobacterium
tuberculosis infection. However, the role of IGRAs for the diagnosis of active tuberculosis (TB), especially in HIV-infected
patients remains unclear.
Methods: We searched PubMed, EMBASE and Cochrane databases to identify studies published in January 2001–July 2011
that evaluated the evidence of using QuantiFERON-TB Gold in-tube (QFT-GIT) and T-SPOT.TB (T-SPOT) on blood for the
diagnosis of active TB in HIV-infected patients.
Results: The search identified 16 eligible studies that included 2801 HIV-infected individuals (637 culture confirmed TB
cases). The pooled sensitivity for the diagnosis of active TB was 76.7% (95%CI, 71.6–80.5%) and 77.4% (95%CI, 71.4–82.6%)
for QFT-GIT and T-SPOT, respectively, while the specificity was 76.1% (95%CI, 74.0–78.0%) and 63.1% (95%CI, 57.6–68.3%)
after excluding the indeterminate results. Studies conducted in low/middle income countries showed slightly lower
sensitivity and specificity when compared to that in high-income countries. The proportion of indeterminate results was as
high as 10% (95%CI, 8.8–11.3%) and 13.2% (95%CI, 10.6–16.0%) for QFT-GIT and T-SPOT, respectively.
Conclusion: IGRAs in their current formulations have limited accuracy in diagnosing active TB in HIV-infected patients, and
should not be used alone to rule out or rule in active TB cases in HIV-infected patients. Further modification is needed to
improve their accuracy.
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Introduction
Tuberculosis (TB) is the most prevalent opportunistic infection
disease and the leading killer in HIV-infected patients. In 2009,
there were an estimated 1.1 million new TB incident cases and 0.4
million TB deaths among HIV positive patients, respectively [1].
Early diagnosis of TB in HIV-infected patients is of great
importance. However, the gold standard for TB diagnosis remains
the detection of Mycobacterium tuberculosis by culture, which is time
consuming. Although the presence of acid-fast bacilli (AFB) in
smear result in any specimen (sputum, needle aspirate, tissue
biopsy) represents some form of mycobacterial disease but does not
always represent TB. Moreover, diagnosis and treatment decisions
may be difficult in cases with clinical suspicion of TB and negative
AFB smear result in any specimen, as smear-positivity can be as
low as 20% in HIV-infected patients [2]. In addition, the clinical
and radiographical signs are often atypical, which further hampers
TB diagnosis [3,4,5,6].
The development of interferon gamma release assays (IGRAs)
offered a new tool for the diagnosis of M.tuberculosis infection.
IGRAs is based on the in vitro stimulation of peripheral blood T-
cells specific using the M.tuberculosis-specific antigens early
secretory antigenic target (ESAT)-6 and culture filtrate protein
(CFP)-10 which is encoded within the region of difference-1, a
region of genome absent in all Bacille de Calmette et Guerin
(BCG) strains and in most nontuberculous mycobacteria [7].The
presence of reactive T-cells is assessed by the induction of
interferon (IFN)-gamma. There are two commercially available
IGRAs currently - the ELISA-based QuantiFERON-TB Gold In
Tube test (QFT-GIT; Cellestis Limited, Australia) and the
ELISPOT-based T-SPOT.TB test (T-SPOT; Oxford Immunotec,
Abingdon, UK).
Since IGRAs can not distinguish active TB from latent TB
infection, and their performance might be impacted by the
immunosuppression in HIV infected patients, their roles in
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established. Based on the available data from general patients and
limited data from HIV-infected patients, many national guidelines
have argued against the use of IGRAs for diagnosing active TB in
HIV infected patients [8,9]. However, many studies still use
IGRAs for this purpose, and some of them recommended their use
for active TB diagnosis in HIV infected patients [10,11]. The
newest systematic review from general patients has showed their
pooled moderate sensitivity and low specificity in diagnosis of
active TB (81% and 79% for QFT-GIT, 92% and 59% for T-
SPOT in confirmed TB cases, respectively) after excluded
indeterminate results. However, the performances of IGRAs in
diagnosis of active TB among HIV-infected individuals were not
specifically assessed [12].
Therefore, we conducted a systematic review and a meta-
analysis in order to support the development of evidence-based
guidance on the use of IGRAs for the diagnosis of active TB in
HIV-infected patients.
Materials and Methods
This systematic review was conducted according to the
guidelines of the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) [13]. We prospectively reregistered
our system review at PROSPERO. (Registration number:
CRD42011001455). The protocol for this meta-analysis support-
ing checklist and flow diagram are available as supporting
information; see Checklist S1, Protocol S1 and Flow Diagram
S1, respectively.
Search strategy
We identified studies that showed the evidence of using IGRAs
in order to diagnose active TB in HIV-infected patients. We
searched PubMed, EMBASE and the Cochrane-controlled central
register of controlled trials and included reports from January
2001 to July 2011. Combinations of the following search terms
were applied: ‘‘tuberculosis’’, ‘‘T-spot’’, ‘‘Quantiferon’’, ‘‘interfer-
on-gamma release assay*’’, ‘‘IGRA*’’, ‘‘ESAT-6’’, ‘‘CFP-10’’,
‘‘HIV’’ and ‘‘human immunodeficiency syndrome’’. We also hand
searched reviews and guidelines, screened citations of all included
studies for additional references.
Study selection
We included all studies that reported the assessment of two
commercially available IGRAs, QFT-GIT and T-SPOT per-
formed on blood sample to diagnose active TB. The following
types of studies were excluded: 1) studies where active tuberculosis
was not confirmed by M. tuberculosis culture or characteristic
histopathological findings (in mixed studies, i.e. those without these
strict criteria, data were analyzed for the confirmed cases
separately. However, if the number of unconfirmed and confirmed
patients was not presented separately, those studies were also
rejected to avoid selection bias.); 2) studies performed with assays
other than QFT-GIT or T-SPOT (in mixed studies, data were
analyzed for the eligible cases separately); 3) studies performed on
non-blood samples; 4)studies not performed and/or interpreted
according to manufacturers’ instructions; 5)studies including fewer
than 10 HIV-infected individuals; 6) studies where selected
patients were treated for TB; 7) conference abstracts, letters
without original data, case reports, editorials, and reviews.
Citations were independently screened by two investigators by
examining titles and abstracts to identify potentially relevant
studies, and differences were resolved by consensus. These original
articles were then retrieved and the full text screened for final
inclusion and data extraction.
Data extraction and Study quality assessment
Data were independently extracted by two reviewers and then
crosschecked. In cases of deviations, final documentation of data was
based on consensus. The following data were extracted: calendar
period of the study, country in which the study was conducted, sex
distribution, enrolled age groups, BCG vaccination status, proportion
of indeterminate results, CD4 T cells count, antiretroviral therapy
status. Country was classified according to the World Bank country
income classification (low/middle-income and high-income), a
surrogate for TB incidence (Available at: http://data.worldbank.
org/about/country-classifications/country-and-lending-groups). Ad-
ditional information not specified in the original article was obtained
by personal correspondence with the authors of the articles if
necessary. The quality of all selected study was assessed using the
QUADAS (Quality Assessment of Diagnostic Accuracy Studies)
checklist, a validated tool for diagnostic accuracy studies [14,15].
Statistical analysis
For each study, we calculated sensitivity or specificity (and 95%
CIs) and summarized the results in forest plots. The sensitivity and
specificity were recalculated using data from the original papers.
Only culture-confirmed cases were deemed active TB, other
patients were all treated as non-active TB. Specificity data in these
studies were derived from non-active TB patients who were
evaluated for active TB. A random-effects meta-analysis was
performed in order to account for the expected between study
variability for each study, along with a pooled estimate using the
MetaDisc software, version 1.4 [16]. Presence of statistically
significant heterogeneity across studies was evaluated by using the
chi-square test for heterogeneity in order to highlight the effect of
true variability rather than sampling error on the overall variation
in diagnostic estimates.
Results
Literature search and study selection
A total of 807 studies were screened for analysis of patients with
active TB using the newest two types of IGRAs from blood in
HIV-infected patients. After full-text review, 16 studies included a
total of 2801 HIV-infected patients (637 HIV-infected with culture
confirmed TB cases) met the inclusion criteria (fig. 1).
Characters of the selected studies
Of the 16 selected studies, 12 evaluated QFT-GIT while 6 used
T-SPOT (2 studies included both of them) [10,11,17,18,19,20,
21,22,23,24,25,26,27,28,29,30]. The median (range) sample size
was 67 (13–830) individuals enrolled per study. The studies
included in the analysis were conducted in 10 different countries,
most of which (70%, 7/10) are low/middle-income countries.
Only 3 high-income countries (Italy, Austria and Spain) were
involved in 4 studies. There are considerably variances among the
studies selected in terms of study design and population
enrollment. Males were more represented than females in most
studies (68.8%, 11/16). The median (range) age in all studies were
37 (33–41). The median (range) CD4 T cells count in all studies
was 180(49–402). Five studies indicated that more than half
patients were under antiretroviral therapy while patients in 3
studies were not. Seven (43.8%) studies included only susceptive
TB cases and 4 (25%) included patients regardless of symptoms
while 5 (31.3%) research conducted on pulmonary TB individuals.
IGRAs in HIV-Infected Patients Systematic Review
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The quality of the selected studies was very high as evaluated by
the QUADAS tool. Study quality indicators were met by 100%
(14/14 items in QUADAS tool) in 11 (68.8%) studies and 93%
(13/14 items) in other 5 (31.3%) researches, thereby increasing the
strength of scientific evidence of our review.
Sensitivity
After excluding the indeterminate results, the pooled sensitivity
of QFT-GIT was 76.7% (95%CI, 71.6–80.5%, I
2=63.3%,
P=0.001, fig. 2A). QFT-GIT conducted in high-income countries
(81.4%; 95%CI, 66.6–91.6%; I
2=0%, P=0.42) showed slightly
higher sensitivity then that in low/middle-income countries
(76.1%; 95%CI, 70.9–80.7%; I
2=73.1%, P,0.001). The pooled
sensitivity of T-SPOT was 77.4% (95%CI, 71.4–82.6%; I
2=0%,
P=0.61, fig. 2B). The sensitivity was 77% (95%CI, 70.1–82%;
I
2=0%, P=0.51) in low/middle-income countries while the only
study from high-income country showed a sensitivity of 84.6%
(95%CI, 54.6–98.1%). The sensitivity of both IGRAs decreased
significantly if indeterminate results were deemed negative. It was
68.7% (95%CI, 62–71.4%; I
2=71.4%, P,0.001) for QFT-GIT
and 65.7% (95%CI, 59.7–71.3%; I
2=69.6%, P,0.01) for T-
SPOT respectively.
Specificity
Four studies enrolled only active TB patients were excluded for
specificity calculation. The pooled specificity of QFT-GIT was
76.1% (95%CI, 74.0–78.0%; I
2=98.2%, P,0.001; fig. 3A). The
specificity from studies conducted in high-income country was
94.2% (95%CI, 92.5–95.6%; I
2=85.5%, P,0.01) when it was just
57% (53.7–60.4%; I
2=8.9%, P=0.36) from research done in
low/middle-income countries. The pooled specificity of T-SPOT
was 63.1% (95%CI, 57.6–68.3%, I
2=77%, P=0.001; fig. 3B)
from all studies. It was 63% (95%CI, 57.3–68.4%; I
2=82%,
P,0.001) in low/middle-income countries while the only study
from high-income country showed a specificity of 64.3% (95%CI,
44.1–81.4%).
Indeterminate results
The pooled proportion of indeterminate results of QFT-GIT
and T-SPOT were 10% (95%CI, 8.8–11.3%) and 13.2% (95%CI,
10.6–16.0%), respectively, as showed in fig. 4. They were slightly
higher when conducted in low/middle-income countries (11.4%;
95%CI,9.7–13.2% and 14.0%; 95%CI 11.4–17.1% for QFT-GIT
and T-SPOT, respectively) comparing to that in high-income
countries (8.4%; 95%CI, 6.8–10.2% and 0%; 95%CI, 0–0.86%
for QFT-GIT and T-SPOT, respectively).
Discussion
Early diagnosis of the active TB is especially needed in HIV
infected cases, since there is an accelerated progression of TB and
higher mortality. Meantime, ruling out active TB in HIV infected
patients prior to isoniazid preventive therapy (IPT) is also
necessary. However, besides M.tuberculosis culture, there are only
limited methods to diagnose active TB with poor accuracy in HIV-
infected patients, which urge the development of alternative, rapid
and accurate method. In this study, we found that IGRAs are
neither sensitive enough to rule out active TB nor specify to
Figure 1. Flow diagram for study selection. IRGAs: Interferon gamma release assays.
doi:10.1371/journal.pone.0026827.g001
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patients.
The sensitivities of both IGRAs in diagnosis of active TB
increased after excluded indeterminate results in HIV-infected
patients. However, they were still not sensitive enough to rule out
active TB alone as they missed more than 20% patients. A recent
meta-analysis by Cattamanchi and colleagues showed the
sensitivities of QFT-GIT and T-SPOT in diagnosis of latent TB
infection in HIV-infected patients were 61% and 72% in low/
middle-income countries (indeterminate results included), respec-
tively when using active TB as a surrogate reference standard [31].
Another meta-analysis from Hoffmann and Ravn showed pooled
sensitivities of 79% and 80.5% for QFT-GIT and T-SPOT in
diagnosis of active TB after excluded indeterminate results
respectively [32]. The slight differences between our results and
theirs may be mainly because they also enrolled studies that active
TB cases were not confirmed by culture and results were not
interpreted according to manufacturer-recommended cut-off
value. The sensitivities of both IGRAs were higher in a recent
meta-analysis performed on general patients (a few studies also
included children and immunosuppressed patients; 81% and
87.5% in their meta-analysis versus 76.7% and 77.4% in ours for
QFT-GIT and T-SPOT, respectively after excluded indetermi-
nate results) [33]. Thus, HIV infection may impact the
performance of IGRAs, which is consistent with results from
others [17,23,34]. However, Tsiouris and colleagues showed no
Figure 2. Sensitivities of IGRAs. Forest plots of pooled sensitivity of QFT QFT-GIT (A) and T-SPOT (B). Date were calcaulated based on all studies
that reported sensitivity of IGRAs after excluding indeterminate results.
doi:10.1371/journal.pone.0026827.g002
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explained by high proportion of active TB cases that under
treatment [35].
The pooled specificities of QFT-GIT, T-SPOT in this analysis
were as low as 75.9%, and 63.1%, respectively, indicating the poor
ability of IGRAs in distinguishing latent TB infection and active
TB. Apparently, the low specificity is due to the high latent TB
infection rate in our selected studies. This is mainly because the
most studies we enrolled were conducted in low/middle-income
countries with a high TB burden. The two studies from Italy and
Austria using QFT-GIT did showed relatively higher specificities.
However, the specificity of T-SPOT was also low in the trail
completed in Italy by Vincenti and colleagues. This may be due to
that nearly one third of non-active TB patients in this study were
from low/middle-income countries (i.e. South American and
African). Thus, IGRAs may potentially have an adjunctive role in
ruling in active TB in HIV-infected patients in high-income
countries, but it still needs further investigation.
The high proportion of indeterminate results of IGRAs in
HIV-infected patients further dampened their application. In
Figure 3. Specificities of IGRAs. Forest plots of pooled specificity of QFT-GIT (A) and T-SPOT (B). Date were calcaulated based on all studies that
reported specificity of IGRAs after excluding indeterminate results.
doi:10.1371/journal.pone.0026827.g003
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results could be mainly because of the high level of immuno-
suppression. Cattamanchi and colleagues showed that the
pooled proportion of indeterminate results was significantly
higher when CD4 T cell count was less than 200 cells/mL
versus greater than 200 cells/mL for QFT-GIT but not T-
SPOT in HIV-infected patients [31]. However, technical error
m i g h ta l s ob eac a u s e .T h ep r o c e d u r eo fT - S P O Tt e s ti s
relatively more technically-demanding than QFT-GIT, partially
explaining the relatively higher indeterminate results of T-
SPOT in this meta-analysis.
There are some limitations in our meta-analysis. Due to our
strict inclusion/exclusion criteria, most studies (or the number of
eligible individuals) were small, especially in terms of the number
of confirmed active TB cases. In addition, number of studies
conducted in high-income countries was limited.
In conclusion, the current evidence brought forward in this
systematic review and meta-analysis shows that the IGRAs in their
current formulations have limited accuracy in diagnosing active
TB in HIV-infected patients, and should not be used alone to rule
out or rule in active TB cases in HIV-infected patients. Further
modification is needed to improve their accuracy.
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